A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
Status:
Completed
Trial end date:
2021-05-20
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is the evaluation of safety and tolerability in patients
with mild to moderate hepatic impairment [Child-Turcotte-Pugh (CTP) classification A and B]
over different dose regimes of BI 685509 compared to placebo. A secondary objective is to
investigate pharmacokinetics of different doses of BI 685509 in patients with mild to
moderate hepatic impairment (CTP A and CTP B). In addition, another secondary objective is to
compare safety, tolerability, and pharmacokinetics in patients with mild to moderate hepatic
impairment (CTP A and CTP B) of single BI 685509 dose to individually matched healthy
volunteers